Distribution of prostate specific antigen (PSA) and percentage free PSA in a contemporary screening cohort with no evidence of prostate cancer

BJU International

Volumn 100, Issue 1, 2007, Pages 37-41

  Chun, Felix K H ^b   Hutterer, Georg C ^a,c   Perrotte, Paul ^d   Gallina, Andrea ^a,e   Valiquette, Luc ^d   Benard, Francois ^d   McCormack, Michael ^d   Briganti, Alberto ^e   Ionescu, Constantin ^a   Jeldres, Claudio ^a   Guay, Jean Pierre ^d   Saad, Fred ^d   Karakiewicz, Pierre I ^a,d  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

^e VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

free PSA; Biopsy; Detection; Prostate cancer; PSA; Screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER SCREENING; COHORT ANALYSIS; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC TEST; HUMAN; LOGISTIC REGRESSION ANALYSIS; MALE; PERIODIC MEDICAL EXAMINATION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; SCREENING TEST;

ADULT; AGED; COHORT STUDIES; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS;

EID: 34249935952     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2007.06923.x     Document Type: Article

References (19)

1. Carter HB. Prostate cancers in men with low PSA levels - must we find them? N Engl J Med 2004 350 : 2292 4
2. Ross KS, Carter HB, Pearson JD, Guess HA. Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection. JAMA 2000 284 : 1399 405
3. Catalona WJ, Smith DS, Ratliff TL et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991 324 : 1156 61
4. Labrie F, Candas B, Cusan L et al. Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial. Prostate 2004 59 : 311 8
5. Fang J, Metter EJ, Landis P, Chan DW, Morrell CH, Carter HB. Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging. Urology 2001 58 : 411 6
6. Schroder FH, van der Cruijsen-Koeter I, de Koning HJ, Vis AN, Hoedemaeker RF, Kranse R. Prostate cancer detection at low prostate specific antigen. J Urol 2000 163 : 806 12
7. Lodding P, Aus G, Bergdahl S et al. Characteristics of screening detected prostate cancer in men 50-66 years old with 3-4 ng/ml prostate specific antigen. J Urol 1998 159 : 899 903
8. Christensson A, Bjork T, Nilsson O et al. Serum prostate specific antigen complexed to α1-antichymotrypsin as an indicator of prostate cancer. J Urol 1993 150 : 100 5
9. Thompson IM, Pauler DK, Goodman PJ et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 2004 350 : 2239 46
10. Horninger W, Cheli CD, Babaian RJ et al. Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2-4 nanograms per milliliter. Urology 2002 60 (Suppl. 1 31 5
11. Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6-4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 1997 277 : 1452 5
12. Loeb S, Roehl KA, Antenor JA, Catalona WJ, Suarez BK, Nadler RB. Baseline PSA compared with median PSA for age group as predictor of pathologic tumor features in men <60 years of age. AUA Meeting Abstracts. J Urol 2005 173 (Suppl. Abstract 533
13. Loeb S, Roehl KA, Antenor JA, Catalona WJ, Suarez BK, Nadler RB. Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old. Urology 2006 67 : 316 20
14. Catalona WJ, Partin AW, Slawin KM et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998 279 : 1542 7
15. Eastham JA, Riedel E, Scardino PT et al. Polyp Prevention Trial Study Group. Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations. JAMA 2003 289 : 2695 700
16. Oesterling JE, Jacobsen SJ, Chute CG et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 1993 270 : 860 4
17. Morgan TO, Jacobsen SJ, McCarthy WF, Jacobson DJ, McLeod DG, Moul JW. Age-specific reference ranges for prostate-specific antigen in black men. N Engl J Med 1996 335 : 304 10
18. Oesterling JE, Jacobsen SJ, Klee GG et al. Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. J Urol 1995 154 : 1090 5
19. Loeb S, Gonzalez CM, Roehl KA et al. Pathological characteristics of prostate cancer detected through prostate specific antigen based screening. J Urol 2006 175 : 902 6